Sangamo splits the R from the D in a reorganization — and bids chief farewell
A lot of big or growing biopharma companies ask themselves whether research and development should be split into two separate groups or headed up by a single top R&D chief. Sangamo $SGMO has been going through that exercise, and came up in favor of a split.
And their senior research exec isn’t going to be in charge of either.
Adrian Woolfson, a Pfizer vet who had been executive vice president of R&D at Sangamo for the past 18 months as the biotech sought to catch up with BioMarin’s hemophilia A gene therapy, has exited the company, according to a statement from Sangamo CEO Sandy Macrae. And Jason Fontenot, SVP of cell therapy, will go forward as interim head of research while the company looks for a new head of development.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.